VGO-Cs01p

N/A

Report date: 2025/04/01 11:31:19

Base Information

Drug NameVGO-Cs01p
Drug Alias NameVGO-Cs01p
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionAnti-CD7Natural killer cell replacementsImmunologic cytotoxicity
TargetsT-cell antigen CD7
Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesShanghai Vitalgen BioPharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Jiao Tong University School of MedicineShanghai Vitalgen BioPharma Co Ltd
Inactive CompaniesN/A
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A